CR20190394A - Compuestos de inhibidores de autotaxina - Google Patents

Compuestos de inhibidores de autotaxina

Info

Publication number
CR20190394A
CR20190394A CR20190394A CR20190394A CR20190394A CR 20190394 A CR20190394 A CR 20190394A CR 20190394 A CR20190394 A CR 20190394A CR 20190394 A CR20190394 A CR 20190394A CR 20190394 A CR20190394 A CR 20190394A
Authority
CR
Costa Rica
Prior art keywords
compounds
divisional
exp
inhibitor compounds
autotaxin
Prior art date
Application number
CR20190394A
Other languages
English (en)
Inventor
John Howard Hutchinson
David Lonergan
Original Assignee
Pharmakea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmakea Inc filed Critical Pharmakea Inc
Publication of CR20190394A publication Critical patent/CR20190394A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos que son inhibidores de autotaxina, métodos para elaborar dichos compuestos, composiciones farmacéuticas y medicamentos que comprenden dichos compuestos, y métodos para utilizar dichos compuestos en el tratamiento de afecciones, enfermedades, o trastornos asociados con actividad autotaxina.Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
CR20190394A 2013-11-22 2014-11-20 Compuestos de inhibidores de autotaxina CR20190394A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907965P 2013-11-22 2013-11-22
US201462038121P 2014-08-15 2014-08-15
PCT/US2014/066706 WO2015077503A1 (en) 2013-11-22 2014-11-20 Autotaxin inhibitor compounds

Publications (1)

Publication Number Publication Date
CR20190394A true CR20190394A (es) 2019-10-29

Family

ID=53180152

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20160289A CR20160289A (es) 2013-11-22 2014-11-20 Compuestos de inhibidor de autotaxina
CR20190394A CR20190394A (es) 2013-11-22 2014-11-20 Compuestos de inhibidores de autotaxina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20160289A CR20160289A (es) 2013-11-22 2014-11-20 Compuestos de inhibidor de autotaxina

Country Status (31)

Country Link
US (7) US9334261B2 (es)
EP (2) EP3071561B1 (es)
JP (1) JP6501367B2 (es)
KR (2) KR102515248B1 (es)
CN (2) CN105793253B (es)
AU (2) AU2014352888B2 (es)
BR (1) BR112016010220B1 (es)
CA (1) CA2930737C (es)
CL (1) CL2016001231A1 (es)
CR (2) CR20160289A (es)
CY (1) CY1124407T1 (es)
DK (1) DK3071561T3 (es)
EA (1) EA030068B1 (es)
ES (1) ES2875899T3 (es)
HK (1) HK1226075A1 (es)
HR (1) HRP20210957T1 (es)
HU (1) HUE055213T2 (es)
IL (2) IL245383B (es)
LT (1) LT3071561T (es)
MX (2) MX2016006623A (es)
MY (1) MY182095A (es)
NI (1) NI201600071A (es)
NZ (1) NZ720478A (es)
PE (1) PE20160654A1 (es)
PH (1) PH12016500862B1 (es)
PL (1) PL3071561T3 (es)
PT (1) PT3071561T (es)
RS (1) RS62027B1 (es)
SI (1) SI3071561T1 (es)
WO (1) WO2015077503A1 (es)
ZA (2) ZA201603083B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2861566T (lt) 2012-06-13 2017-02-10 F. Hoffmann-La Roche Ag Nauji diazaspirocikloalkanai ir azaspirocikloalkanai
CA2878442A1 (en) 2012-09-25 2014-04-03 F. Hoffmann-La Roche Ag Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9714240B2 (en) 2013-09-17 2017-07-25 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
US9951026B2 (en) 2013-09-17 2018-04-24 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
WO2015048301A1 (en) 2013-09-26 2015-04-02 Pharmakea, Inc. Autotaxin inhibitor compounds
CR20160289A (es) 2013-11-22 2016-09-27 Pharmakea Inc Compuestos de inhibidor de autotaxina
MX2016006688A (es) 2013-11-22 2016-11-29 Pharmakea Inc Inhibidores tetraciclicos de autotaxina.
SI3074400T1 (en) 2013-11-26 2018-03-30 F. Hoffmann-La Roche Ag Octahydro-cyclobut (1,2-c, 3,4-cy) dipyrrole derivatives as autoantaxine inhibitors
CN106029667B (zh) 2014-03-26 2019-08-23 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的稠合[1,4]二氮杂*化合物
UA118582C2 (uk) 2014-03-26 2019-02-11 Ф. Хоффманн-Ля Рош Аг Біциклічні сполуки як інгібітори продукції аутотаксину (atx) і лізофосфатидилової кислоти (lpa)
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AU2016268250B2 (en) 2015-05-27 2020-08-27 Sabre Therapeutics Llc Autotaxin inhibitors and uses thereof
MX2020004504A (es) 2015-09-04 2021-11-10 Hoffmann La Roche Derivados de fenoximetilo.
JP6846414B2 (ja) 2015-09-24 2021-03-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａｔｘ阻害剤としての二環式化合物
MX2017015034A (es) 2015-09-24 2018-04-13 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
CA2991615A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
US11000142B2 (en) 2016-12-06 2021-05-11 John Joseph Girard Flexible floor mat incorporating LED lighting
WO2018167001A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as dual atx/ca inhibitors
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
MX2020002241A (es) 2017-08-28 2020-09-03 Angiex Inc Anticuerpos anti-tm4sf y métodos de uso de los mismos.
WO2023215196A1 (en) * 2022-05-03 2023-11-09 Sabre Therapeutics Llc Polymorphic and salt forms of the autotaxin inhibitor cudetaxestat
CN116239577A (zh) * 2023-03-27 2023-06-09 沈阳药科大学 一种制备Cudetaxestat的方法
CN116396205A (zh) * 2023-04-20 2023-07-07 沈阳药科大学 一种n-芳基吲哚衍生物及其制备方法和应用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210574A (en) 1991-03-08 1993-05-11 Mita Industrial Co., Ltd. Photosensitive drum body-mounting mechanism including a drive coupling member with a coupling protrusion adapted to bite into the inner surface of the mechanism's photosensitive drum
US5186522A (en) 1991-09-24 1993-02-16 Midland Brake, Inc. Air dryer purge line
CA2126859A1 (en) 1992-11-10 1994-05-26 Charles N. Goloff Solenoid valve assembly
US5407368A (en) 1992-12-15 1995-04-18 Minnesota Mining And Manufacturing Company Electrode connector
US5761473A (en) 1993-01-08 1998-06-02 International Business Machines Corporation Method and system for increased instruction synchronization efficiency in a superscalar processsor system utilizing partial data dependency interlocking
US5564949A (en) 1995-01-05 1996-10-15 Thomas & Betts Corporation Shielded compact data connector
JP2664048B2 (ja) 1995-03-27 1997-10-15 科学技術庁金属材料技術研究所長 六フッ化二ケイ素の合成法
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
WO2001030343A1 (en) 1999-10-22 2001-05-03 Merck & Co., Inc. Pharmaceuticals for treating obesity
US6890933B1 (en) 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
ES2267831T3 (es) 2000-10-03 2007-03-16 Lilly Icos Llc Derivados de piridoindol condensado.
BR0208790A (pt) 2001-04-11 2004-03-30 Idenix Cayman Ltd Fenilindoìs para o tratamento de hiv
KR20040047862A (ko) * 2001-09-27 2004-06-05 에프. 호프만-라 로슈 아게 Ｃｏｘ ⅱ 억제제로서의 인돌 유도체
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
ES2342596T3 (es) 2002-08-29 2010-07-09 MERCK SHARP & DOHME CORP. Indoles con actividad anti-diabetica.
AU2003260085B2 (en) 2002-08-29 2008-09-11 Merck & Co., Inc. Indoles having anti-diabetic activity
CN1791592B (zh) 2003-05-19 2012-07-04 Irm责任有限公司 免疫抑制剂化合物和组合物
BRPI0417858B1 (pt) 2003-12-23 2017-10-10 H. Lundbeck A/S Derivative compounds of aniline and pharmaceutical composition that understand it
JP4714143B2 (ja) 2004-05-19 2011-06-29 住友電気工業株式会社 Ｉｉｉ族窒化物半導体結晶の製造方法
KR101141650B1 (ko) 2004-09-30 2012-05-17 엘지전자 주식회사 매체접속제어 계층에서의 데이터 처리 방법 및 이동통신용단말
WO2006041961A1 (en) 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
US20080319044A1 (en) 2004-11-01 2008-12-25 Nuada, Llc Compounds and Methods of Use Thereof
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20060270634A1 (en) 2005-05-06 2006-11-30 Miller Duane D Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
AR054394A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
WO2007041600A2 (en) 2005-10-03 2007-04-12 Luminescent Technologies, Inc. Mask-pattern determination using topology types
JP5081161B2 (ja) 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
CA2690762C (en) 2007-06-15 2016-06-14 Glenn Prestwich .alpha.-chloro and .alpha.-bromo phosphonate analogs of lysophosphatidic acid and methods of making and using thereof
DE102007047737A1 (de) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
DE102007047735A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
DE102007047738A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
US8268891B1 (en) 2007-11-13 2012-09-18 University Of Memphis Research Foundation Autotaxin inhibitors
US8378100B2 (en) 2008-01-09 2013-02-19 University Of Virginia Patent Foundation Phosphonate derivatives as autotaxin inhibitors
WO2009151644A2 (en) 2008-06-13 2009-12-17 Yale University Small molecule inhibitors of autotaxin methods of use
WO2010040080A1 (en) 2008-10-03 2010-04-08 Abby Louise Parrill-Baker Mechanism-based inactivators of autotaxin
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
CA2745041C (en) 2008-12-01 2017-08-22 Kai Schiemann 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer
EP2626072B1 (en) 2009-04-02 2019-12-04 Merck Patent GmbH Piperidine and piperazine derivatives as autotaxin inhibitors
KR20120027192A (ko) 2009-04-02 2012-03-21 메르크 파텐트 게엠베하 오토탁신 저해제로서의 헤테로시클릭 화합물
MX2011010218A (es) 2009-04-02 2011-10-10 Merck Patent Gmbh Inhibidores de autotaxina.
US8445200B2 (en) 2009-04-15 2013-05-21 The Regents Of The University Of California Genotoxicity as a biomarker for inflammation
SG175993A1 (en) 2009-05-11 2011-12-29 Berg Biosystems Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2763016C (en) 2009-05-20 2018-04-17 Eth Zurich Targeting micrornas for metabolic disorders
US8343934B2 (en) 2009-06-30 2013-01-01 University Of Memphis Diverse lead compound autotaxin inhibitors
DE102009033392A1 (de) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
DE102009049211A1 (de) 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
WO2011049433A1 (en) 2009-10-23 2011-04-28 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Diagnosis and treatment of pruritis
US8497371B2 (en) 2009-10-26 2013-07-30 University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
WO2011053597A1 (en) 2009-10-26 2011-05-05 The University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
WO2011103430A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
AU2011232058B2 (en) * 2010-03-26 2016-09-08 Merck Patent Gmbh Benzonaphthyridinamines as autotaxin inhibitors
US20130116171A1 (en) 2010-04-16 2013-05-09 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
CN103201262B (zh) * 2010-08-20 2016-06-01 艾米拉医药股份有限公司 自分泌运动因子抑制剂及其用途
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
US8673882B2 (en) 2011-01-20 2014-03-18 University Of Tennessee Research Foundation Inhibitors of autotaxin
US9035056B2 (en) 2011-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
JP2014505737A (ja) 2011-02-18 2014-03-06 メディベイション テクノロジーズ， インコーポレイテッド 糖尿病を処置する化合物および方法
EP2685976B1 (en) 2011-03-17 2017-12-27 Tel HaShomer Medical Research Infrastructure and Services Ltd. Quinolone analogs for treating autoimmune diseases
EP2714680B1 (en) * 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
GB2494154B (en) 2011-08-31 2017-11-29 Metaswitch Networks Ltd Conditional telecommunications
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
US9273011B2 (en) 2011-10-28 2016-03-01 Inhibitaxin Limited Substituted pyridazines for the treatment of pain
JP2013129632A (ja) 2011-12-22 2013-07-04 Ono Pharmaceut Co Ltd Ｅｎｐｐ２阻害化合物
US20130270634A1 (en) 2012-04-12 2013-10-17 Richtek Technology Corporation High voltage device and manufacturing method thereof
LT2861566T (lt) 2012-06-13 2017-02-10 F. Hoffmann-La Roche Ag Nauji diazaspirocikloalkanai ir azaspirocikloalkanai
WO2014031170A1 (en) 2012-08-22 2014-02-27 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
CA2878442A1 (en) 2012-09-25 2014-04-03 F. Hoffmann-La Roche Ag Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
WO2014097151A2 (en) 2012-12-19 2014-06-26 Novartis Ag Autotaxin inhibitors
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
TWI499591B (zh) 2013-01-11 2015-09-11 Lilly Co Eli 雙環嘧啶化合物
US9951026B2 (en) 2013-09-17 2018-04-24 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
US9714240B2 (en) 2013-09-17 2017-07-25 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
WO2015048301A1 (en) 2013-09-26 2015-04-02 Pharmakea, Inc. Autotaxin inhibitor compounds
PE20160905A1 (es) 2013-11-05 2016-09-24 Bayer Cropscience Ag Benzamidas sustituidas para el tratamiento de artropodos
CL2016001118A1 (es) 2013-11-22 2016-12-02 Basf Se Compuestos heterocíclicos de n-acilimino
CR20160289A (es) 2013-11-22 2016-09-27 Pharmakea Inc Compuestos de inhibidor de autotaxina
US9783523B2 (en) 2013-11-22 2017-10-10 Basf Se N-acylimino heterocyclic compounds
MX2016006688A (es) 2013-11-22 2016-11-29 Pharmakea Inc Inhibidores tetraciclicos de autotaxina.
US9051320B1 (en) * 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
AU2016268250B2 (en) 2015-05-27 2020-08-27 Sabre Therapeutics Llc Autotaxin inhibitors and uses thereof

Also Published As

Publication number Publication date
AU2014352888B2 (en) 2019-05-09
US9468628B2 (en) 2016-10-18
CA2930737A1 (en) 2015-05-28
US9334261B2 (en) 2016-05-10
ZA201603083B (en) 2022-03-30
US20200268713A1 (en) 2020-08-27
US20160046614A1 (en) 2016-02-18
AU2019213425B2 (en) 2021-01-07
MX2016006623A (es) 2017-03-10
EA030068B1 (ru) 2018-06-29
EP3071561A1 (en) 2016-09-28
HUE055213T2 (hu) 2021-11-29
JP2016537389A (ja) 2016-12-01
US10688081B2 (en) 2020-06-23
CA2930737C (en) 2023-02-21
EA201690881A1 (ru) 2016-12-30
JP6501367B2 (ja) 2019-04-17
PT3071561T (pt) 2021-06-25
US20160235713A1 (en) 2016-08-18
LT3071561T (lt) 2021-08-25
KR20220027276A (ko) 2022-03-07
NI201600071A (es) 2016-09-21
US20180243267A1 (en) 2018-08-30
US11779568B2 (en) 2023-10-10
RS62027B1 (sr) 2021-07-30
US20240189281A1 (en) 2024-06-13
BR112016010220B1 (pt) 2023-05-09
MX2020009780A (es) 2020-10-12
IL245383B (en) 2019-11-28
CN110372671B (zh) 2023-02-21
EP3878848A1 (en) 2021-09-15
ES2875899T3 (es) 2021-11-11
US9999615B2 (en) 2018-06-19
KR20160079082A (ko) 2016-07-05
NZ720478A (en) 2022-02-25
WO2015077503A8 (en) 2015-07-16
PH12016500862A1 (en) 2016-07-18
PE20160654A1 (es) 2016-07-15
DK3071561T3 (da) 2021-06-21
CR20160289A (es) 2016-09-27
IL245383A0 (en) 2016-06-30
BR112016010220A2 (pt) 2018-05-02
EP3071561A4 (en) 2017-04-12
KR102367876B1 (ko) 2022-02-24
HK1226075A1 (zh) 2017-09-22
WO2015077503A1 (en) 2015-05-28
SI3071561T1 (sl) 2021-11-30
PL3071561T3 (pl) 2021-11-08
CN110372671A (zh) 2019-10-25
AU2014352888A1 (en) 2016-06-09
US11344533B2 (en) 2022-05-31
ZA202005029B (en) 2022-02-23
EP3071561B1 (en) 2021-03-24
CL2016001231A1 (es) 2017-01-20
US20160374991A1 (en) 2016-12-29
HRP20210957T1 (hr) 2021-09-17
MY182095A (en) 2021-01-18
CN105793253B (zh) 2019-08-23
AU2019213425A1 (en) 2019-08-29
CN105793253A (zh) 2016-07-20
KR102515248B1 (ko) 2023-03-29
PH12016500862B1 (en) 2016-07-18
IL270168B (en) 2022-02-01
CY1124407T1 (el) 2022-07-22
US20220265608A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
CR20190394A (es) Compuestos de inhibidores de autotaxina
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CR20180374A (es) Compuestos heterocíclicos como inmunomoduladores
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
CR20170478A (es) Compuestos novedosos
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
NI201500115A (es) Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112017018198A2 (pt) inibição da atividade de olig2
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
BR112015016391A2 (pt) carboxamidas i baseadas em pirazolil como inibidoras do canal crac